Curis Announces Presentations at 102nd American Association for Cancer Research Annual Meeting 2011

LEXINGTON, Mass.--(BUSINESS WIRE)-- Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that its scientists will present preclinical data for three of its oncology programs at the upcoming 102nd American Association for Cancer Research (AACR) Annual Meeting to be held in Orlando, Florida at the Orange County Convention Center on April 2-6, 2011.

Curis scientists will make two presentations related to Curis-controlled proprietary compounds, CUDC-101 and CUDC-907. CUDC-101 is a first-in-class EGFR, Her2 and HDAC inhibitor and is currently the subject of a Phase I expansion clinical trial. CUDC-907 is a dual PI3 kinase and HDAC inhibitor, and Curis expects that it will file an investigational new drug application (IND) for CUDC-907 in the fourth quarter of 2011 and begin Phase I clinical testing shortly thereafter.

Both compounds are designed as highly specific, multi-target inhibitors with the aim of achieving greater efficacy through durable cancer network disruption.

Curis is also presenting data on Debio 0932 (formerly CUDC-305), a wholly-synthetic oral HSP90 inhibitor that is licensed to Debiopharm and is currently in Phase I clinical testing.

The presentations are as follows:

Monday, April 4, 2011, 1:00 - 5:00 PM EDT
Location: Exhibit Hall A4-C, Poster Section 29
Session: Experimental and Molecular Therapeutics 18
Presentation Title: Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR and HER2 inhibitor, on preventing drug resistance and tumor metastasis
Presenter: Jing Wang, Ph.D., Staff Scientist of Molecular and Cellular biology

Monday, April 4, 2011, 1:00 - 5:00 PM EDT
Location: Exhibit Hall A4-C, Poster Section 29
Session: Experimental and Molecular Therapeutics 18
Presentation Title: Antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models
Presenter: Rudi Bao, M.D., Ph.D., Senior Director, Oncology

Tuesday, April 5, 2011, 8:00 AM - 12:00 PM EDT
Location: Exhibit Hall A4-C, Poster Section 16
Session: Cancer Chemistry 8
Presentation Title: Design and synthesis of imidazopyridine derivatives as novel HSP90 inhibitors for the treatment of cancer
Presenter: Xiong Cai, Ph.D., Vice President, Medicinal Chemistry

Copies of the posters will be available on Curis’ website, www.curis.com, following the presentations.

About Curis, Inc.

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.

Curis Cautionary Statement: This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements used in this press release may contain the words "believes", "expects", "anticipates", "plans", "seeks", "estimates”, “assumes”, "will", "may" or similar expressions. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, assumptions and other important factors that may cause the actual results to be materially different from those indicated by such forward-looking statements including, among other things Those risk factors identified in Curis’ Annual Report on Form 10-K for the year ended December 31, 2010 and other filings that it periodically makes with the Securities and Exchange Commission.

In addition, any forward-looking statements represent the views only as of today and should not be relied upon as representing Curis' views as of any subsequent date. Curis disclaims any intention or obligation to update any of the forward-looking statements after the date of this press release whether as a result of new information, future events or otherwise.



CONTACT:

Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial and Chief Operating Officer
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Women  Health  Biotechnology  Clinical Trials  Genetics  Oncology  Pharmaceutical  Consumer

MEDIA:

Logo
 Logo

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.